Skip to search formSkip to main contentSkip to account menu

Response Evaluation Criteria in Solid Tumors

Known as: RECIST 
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve…
Highly Cited
2016
Highly Cited
2016
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.
9504Background: In the phase III KEYNOTE-006 study (NCT01866319), pembro (anti–PD-1) provided superior OS and PFS and a lower… 
Highly Cited
2016
Highly Cited
2016
Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.
7 Background: PD-L1 and PD-L2 expression have been associated with poor prognosis in esophageal cancer. Pembrolizumab (pembro) is… 
Highly Cited
2014
Highly Cited
2014
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in… 
Highly Cited
2012
Highly Cited
2012
The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria
PurposeThis study evaluated the ability of 18F-FDG PET/CT imaging to predict early response to 90Y-radioembolization in… 
Highly Cited
2012
Highly Cited
2012
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient
Dendritic cells (DCs) electroporated with mRNA encoding CD70, CD40L and a constitutively active toll-like receptor 4 (TriMix-DC… 
Review
2006
Review
2006
Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy
Response evaluation criteria in solid tumors (RECIST) guidelines were published in 2000 to evaluate response to treatment in… 
Review
2006
Review
2006
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
Highly Cited
2004
Highly Cited
2004
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.
4500 Background: SU011248 is an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… 
2002
2002
Outstanding problems with Response Evaluation Criteria in Solid Tumors (RECIST) in breast cancer
BackgroundIn 1999 European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)